Independent predictors of the severity of liver disease (presence of NASH and clinically significant fibrosis, i.e. stage >1) at multivariate logistic regression analysis in 159 patients with histological NAFLD.

<p>OR: odds ratio; c.i.: confidence interval; high risk of OSAS with sleepiness: positivity for both BQ and ESS vs. all other patients. BMI: body mass index; IFG: impaired fasting glucose; ALT: alanine aminotransferases.</p

Association between high risk for OSAS with sleepiness (BQ+ESS+) vs. low risk (all other patients) with histological severity of liver disease (prevalence of NASH and of clinically significant fibrosis, i.e. stage >1) in 159 non-morbidly obese patients with histological NAFLD.

<p>Association between high risk for OSAS with sleepiness (BQ+ESS+) vs. low risk (all other patients) with histological severity of liver disease (prevalence of NASH and of clinically significant fibrosis, i.e. stage >1) in 159 non-morbidly obese patients with histological NAFLD.</p

Demographic and clinical features of 159 NAFLD patients according to the risk of OSAS with or without daytime sleepiness.

<p>Data are shown as Mean ± SD (% values) according to data distribution; P value: at ANOVA; *P<0.05 vs. BQ− (t-test or Chi-square according to data distribution); BMI: body mass index; HOMA-IR: homeostasis metabolic assessment insulin resistance index; IFG: impaired fasting glucose; ALT: alanine aminotransferases; GGT: gamma-glutamyl-transferase.</p

Prevalence of positivity for BQ alone (BQ+ESS−), ESS alone (BQ−ESS+), and both BQ and ESS (BQ+ESS+) in 159 non-morbidly obese patients with histological NAFLD and 80 matched controls without ultrasonographic evidence of hepatic steatosis.

<p>P = ns: not significant.</p

Association between high risk for OSAS with sleepiness (BQ+ESS+) vs. low risk (all other patients) with histological severity of liver disease as determined by components of NAFLD activity score (panel A: steatosis grade, panel B: necroinflammation, panel C: ballooning, panel D: fibrosis stage) in 159 non-morbidly obese patients with histological NAFLD.

<p>Association between high risk for OSAS with sleepiness (BQ+ESS+) vs. low risk (all other patients) with histological severity of liver disease as determined by components of NAFLD activity score (panel A: steatosis grade, panel B: necroinflammation, panel C: ballooning, panel D: fibrosis stage) in 159 non-morbidly obese patients with histological NAFLD.</p

Demographic and clinical features of 159 non-morbidly obese patients with histological NAFLD subdivided according to the presence of NASH.

<p>Data are shown as Mean ± SD (% values); according to data distribution; BMI: body mass index; IFG: impaired fasting glucose; HOMA-IR: homeostasis metabolic assessment insulin resistance index; ALT: alanine aminotransferases; GGT: gamma-glutamyl-transferase.</p

Association between SVR and IL28B genotype.

<p>All treated patients (gray) or patients receiving triple therapy (white) were analysed by cirrhosis status and IL28 CC or non CC.</p

Characteristics of naïve candidate patients by physician decision to treat or not.

<p>*IL28B rs12979860 undetermined in 47 cases among treated patients; ^§ not available in 22 cases among treated patients.</p><p>Characteristics of naïve candidate patients by physician decision to treat or not.</p

Baseline factors orienting physician choices FOR TVR or BOC.

<p>*IL28B rs12979860 undetermined in 40 patients treated with TVR and 1 treated with BOC; ^§not available in 13 cases among patients treated with TVR and in 9 patients treated with BOC</p><p>Baseline factors orienting physician choices FOR TVR or BOC.</p

Patient disposition in the study.

<p>Patient disposition in the study.</p